Subject:
- Active Substance: Abrocitinib
- Name: Cibinqo®
- Therapeutic area: Atopic dermatitis
- Pharmaceutical company: Pfizer Pharma GmbH
Time table:
- Start: 15.01.2022
- Final decision by G-BA: 07.07.2022
Final decision:
- Hint for a considerable additional benefit